Nasdaq:TELA
TELA Bio, Inc.
A clinical-stage biotech firm developing oral small-molecule therapies for autoimmune diseases such as psoriasis and alopecia areata.
Key Metrics
Investment Thesis
Bull Case
Investors may consider TELA Bio attractive due to its robust partnership ecosystem that generates revenue without requiring massive commercial infrastructure investments. The transition from large net losses suggests the company is maturing financially while maintaining a valuable pipeline of differentiated oral therapies. Strategic collaborations reduce the capital intensity required for development, potentially leading to a more sustainable burn rate as clinical milestones are achieved.
Bear Case
The persistent negative cash flow from operations and a significant accumulated deficit indicate that the company has not yet achieved commercial viability or self-sufficiency. Heavy reliance on external funding creates vulnerability if market conditions tighten or if key partnerships fail to deliver expected returns. The high marketing and administrative expenses relative to revenue suggest that current financial structures are inefficient for a pre-revenue biotechnology firm.
About TELA Bio, Inc.
TELA Bio, Inc. is a clinical-stage biotechnology company focused on developing innovative therapies for autoimmune diseases, particularly targeting conditions like psoriasis and alopecia areata. The company serves patients globally through its proprietary pipeline of small molecule drugs designed to modulate the immune system with high specificity. Key products under development include oral treatments intended to offer more convenient alternatives to current injectable biologic therapies.
Analysis
Management Discussion
Despite a net loss of $37.8M in 2024, TELA Bio achieved a notable reduction in its deficit compared to previous years, reflecting improved operational efficiency and successful partnership negotiations. Revenue growth accelerated to $69.3M, driven by strong collaboration milestones and royalties, indicating increasing market validation of its technology platform. The company maintained a healthy cash position with $52.7M in cash and equivalents, providing sufficient runway to fund upcoming clinical phases without immediate dilution.
Industry Overview
The biotechnology sector is characterized by high innovation cycles where companies must navigate rigorous regulatory pathways to bring novel therapies to market. Success in this industry often depends on forming strategic alliances with larger pharmaceutical firms to share the substantial costs of clinical trials and distribution. Investors face binary outcomes where successful drug approvals can lead to exponential value creation while failures can result in total capital erosion.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $41.4M | $58.5M | $69.3M |
| Cost of Revenue | $13.6M | $18.0M | $22.4M |
| Gross Profit | $27.0M | $40.1M | $46.5M |
| Operating Expenses | $66.1M | $84.2M | $88.2M |
| Operating Income | $-39.0M | $-44.1M | $-34.1M |
| R&D | $8.9M | $9.6M | $8.8M |
| G&A | $13.9M | $14.9M | $14.7M |
| Marketing | $43.3M | $59.7M | $64.6M |
| Stock-Based Comp | $4.0M | $5.0M | $4.4M |
| Depreciation | $383.0K | $428.0K | $632.0K |
| Other OpEx | $0 | $0 | $0 |
| Non-Operating Income | $0 | $0 | $-3.9M |
| Interest Expense | $4.1M | $5.2M | — |
| Pre-Tax Income | $-39.0M | $-44.1M | $-38.0M |
| Income Tax | $5.3M | $2.6M | $-144.0K |
| Continuing Ops | $-44.3M | $-46.7M | $-37.8M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-44.3M | $-46.7M | $-37.8M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-44.3M | $-46.7M | $-37.8M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $62.4M | $71.7M | $78.1M |
| Cash & Equivalents | $42.0M | $46.7M | $52.7M |
| Inventory | $11.8M | $13.2M | $12.8M |
| Prepaid Expenses | $2.0M | $2.1M | $2.5M |
| Other Current Assets | $6.6M | $9.7M | $10.1M |
| Long-Term Assets | $5.4M | $6.3M | $8.5M |
| PP&E (Net) | $1.7M | $2.0M | $2.3M |
| Intangibles | $2.5M | $2.1M | $1.7M |
| Operating Leases | $1.2M | $2.0M | $1.7M |
| Other LT Assets | $0 | $265.0K | $2.7M |
| Total Assets | $67.9M | $78.0M | $86.6M |
| Current Liabilities | $12.4M | $17.0M | $15.6M |
| Accounts Payable | $1.5M | $1.7M | $2.1M |
| Current Leases | $340.0K | $565.0K | $545.0K |
| Other Current Liab | $-340.0K | $-565.0K | $-545.0K |
| Long-Term Liabilities | $41.1M | $42.2M | $42.5M |
| Long-Term Debt | $39.9M | $40.5M | $41.1M |
| LT Operating Leases | $1.2M | $1.7M | $1.4M |
| Other LT Liab | $31.0K | $-15.0K | $-10.0K |
| Total Liabilities | $53.5M | $59.2M | $58.1M |
| Shareholders' Equity | $14.3M | $18.9M | $28.5M |
| Paid-In Capital | $288.4M | $339.7M | $387.1M |
| Retained Earnings | $-274.2M | $-320.9M | $-358.7M |
| AOCI | $150.0K | $91.0K | $90.0K |
| Total L&E | $67.9M | $78.0M | $86.6M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-44.3M | $-46.7M | $-37.8M |
| Non-Cash Adjustments | $-5.2M | $-4.2M | $-5.9M |
| Working Capital Changes | $8.8M | $10.0M | $2.2M |
| Cash from Operations | $-40.7M | $-40.9M | $-41.6M |
| Capital Expenditures | $872.0K | $611.0K | $989.0K |
| Cash from Investing | $-1.9M | $-599.0K | $4.5M |
| Debt Issuances | $40.0M | — | — |
| Debt Repayments | $30.0M | — | — |
| Cash from Financing | $40.9M | $46.3M | $43.1M |
| FX Effect | $-144.0K | $164.0K | $28.0K |
| Net Change in Cash | $-1.9M | $5.0M | $5.9M |
| Beginning Cash | $43.9M | $42.0M | $47.0M |
| Ending Cash | $42.0M | $47.0M | $52.9M |
Frequently Asked Questions
How does TELA Bio, Inc. make money?
The company's revenue is derived primarily from collaborations with third-party pharmaceutical companies, including milestone payments and royalties related to its drug candidates. Revenue streams also include licensing agreements where TELA provides technology or assets in exchange for upfront fees and future sales-based payments. Current operations reflect a typical pre-revenue biotech model reliant on strategic partnerships rather than direct commercial sales.
What are the main risks for TELA?
The company faces substantial risk of failure in ongoing or future clinical trials, which could result in significant write-downs or loss of partnership value. As a pre-commercial entity, TELA Bio relies heavily on external funding sources to cover its high cash burn rate and operational expenses. Potential regulatory hurdles from the FDA regarding the approval of novel mechanisms could delay market entry and impact revenue projections. Intellectual property disputes or challenges to patent validity could erode the competitive moat protecting the company's drug candidates.
What is TELA's competitive advantage?
TELA Bio possesses significant intellectual property portfolios covering novel small-molecule compounds that offer differentiated mechanisms of action compared to existing injectable biologics. The company leverages its proprietary drug discovery platform which accelerates the development timeline and reduces costs associated with bringing new therapies to market. Strategic partnerships with major pharmaceutical entities provide validated commercial pathways and shared financial risk for large-scale clinical trials.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.